Primary Objective: 1. To assess the safety, toxicity, and feasibility of using epigenetic therapy in the perioperative setting for men undergoing radical prostatectomy (RP). 2. To assess the feasibility of measuring changes in gene expression (in radical prostatectomy [RP] tissue) induced by epigenetic modifiers at conventional doses with a focus on Interferon Stimulated Genes. Secondary Objectives: 1. To estimate the biochemical progression free survival in men treated with epigenetic therapy prior to prostatectomy.